These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Vasopressin and vasopressin antagonists in heart failure and hyponatremia. Farmakis D; Filippatos G; Kremastinos DT; Gheorghiade M Curr Heart Fail Rep; 2008 Jun; 5(2):91-6. PubMed ID: 18765079 [TBL] [Abstract][Full Text] [Related]
8. Role of vaptans in the management of hyponatremia. Lehrich RW; Ortiz-Melo DI; Patel MB; Greenberg A Am J Kidney Dis; 2013 Aug; 62(2):364-76. PubMed ID: 23725974 [TBL] [Abstract][Full Text] [Related]
9. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Verbalis JG Cleve Clin J Med; 2006 Sep; 73 Suppl 3():S24-33. PubMed ID: 16970150 [TBL] [Abstract][Full Text] [Related]
10. Vasopressin receptor antagonists in heart failure. Hobbs RE; Tang WH Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):177-84. PubMed ID: 18232127 [TBL] [Abstract][Full Text] [Related]
11. Clinical review: the use of vaptans in clinical endocrinology. Peri A J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044 [TBL] [Abstract][Full Text] [Related]
13. Treatment of hyponatremia: the role of lixivaptan. Liamis G; Filippatos TD; Elisaf MS Expert Rev Clin Pharmacol; 2014 Jul; 7(4):431-41. PubMed ID: 24766294 [TBL] [Abstract][Full Text] [Related]
14. Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists? Valania G; Singh M; Slawsky MT Curr Heart Fail Rep; 2011 Sep; 8(3):198-205. PubMed ID: 21046492 [TBL] [Abstract][Full Text] [Related]
15. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review. Nemerovski C; Hutchinson DJ Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957 [TBL] [Abstract][Full Text] [Related]